Cardiomyopathy Diagnosis
Cardiomyopathy Diagnosis
The diagnosis of cardiomyopathy is not made by a single test. Echocardiography describes the shape the muscle has taken; cardiac MRI describes what the tissue is made of; the electrical assessment establishes what the heart is at risk of; blood markers and, increasingly, genetic testing identify the cause. Each of these answers a different question, and the value of the pathway comes from the order in which they are asked. This page sets out what each test contributes, what it cannot do, and what a completed assessment should be able to state in writing.
Echocardiography: the scan that names the pattern
Every pathway starts here. An echocardiogram uses ultrasound to show the thickness of the walls, the size of the chambers, how each segment of muscle moves, how the valves are working and how the heart fills — and it does so without radiation and without a catheter. Its first job in cardiomyopathy is not to measure how well the heart is pumping but to establish which pattern the muscle has taken.
| What the scan answers | The measurement behind it | Where it reaches its limit |
|---|---|---|
| What shape has the muscle taken? | Wall thickness at defined segments, chamber dimensions, the relationship between wall and cavity, and whether the thickening is symmetric or focal | A heart thickened only at the apex, or an early and subtle change, can be missed by a study that was not asked to look for it |
| How well does it pump? | The ejection fraction, and how much each segment of wall thickens and moves during contraction | A normal ejection fraction is compatible with important disease, because filling rather than squeezing is often what fails first |
| Is there an obstruction? | The Doppler gradient across the outflow tract, at rest and with a provocation such as standing up, a Valsalva manoeuvre or exercise | The gradient is dynamic; a resting study can be unremarkable in a patient who obstructs on a treadmill |
| How does it fill? | Mitral inflow, tissue Doppler velocities and the size of the left atrium — the indirect signs of a stiff chamber | Filling measurements depend on the volume in the heart at the time; the same heart measures differently when the patient is dry and when the patient is congested |
| Is anything else involved? | Valve structure and function, the right ventricle, the pericardium, and an estimate of the pressures in the lungs | Not all of the muscle is equally visible; the right ventricle and the apex need dedicated views to be assessed properly |
Two practical points follow. The first is that echocardiography is question-dependent as well as operator-dependent: the same heart imaged to answer "why is this patient breathless" and imaged to answer "what type of cardiomyopathy is this" produces two different studies, because the second one is looking at different things. The second is that echo is the beginning of the pathway rather than the end of it. What it cannot say about tissue is precisely what MRI is for, and a normal scan in a relative does not conclude that relative's screening — it resets the clock on it.
Cardiac MRI: what the tissue is made of
Echocardiography describes the shape of the muscle; cardiac MRI describes the tissue. In cardiomyopathy that is not a refinement but frequently the step that turns a description into a diagnosis. The scan measures wall thickness and chamber size precisely, but its real contribution is the characterisation of the muscle itself.
- Scar. Late gadolinium enhancement shows where muscle has been replaced by fibrous tissue. Both its presence and its distribution matter — a scar in the middle of a thickened septum points one way, a scar immediately under the lining of the muscle points another — and the amount of scar feeds directly into the estimate of rhythm risk.
- Deposition. Mapping techniques such as T1 and T2 mapping and extracellular volume measurement detect the expansion of the space between muscle cells, which is the signature of amyloid, of oedema and of iron overload — sometimes before the wall has thickened at all.
- Fat and scar in the right ventricle. In arrhythmogenic disease the MRI is where the diagnosis is usually made: the regional wall-motion abnormality and the fatty replacement are the finding itself, not a footnote to it.
- Function under stress. Stress perfusion imaging can show whether the muscle runs short of blood, including in patients whose coronary arteries are normal but whose thickened muscle has outgrown the supply it needs.
Three caveats belong here. MRI is not suitable for everyone: certain implanted devices, metallic fragments, severe kidney impairment and an inability to lie still for the length of the scan can rule it out, and contrast echocardiography, CT or nuclear imaging is substituted to answer as much of the same question as possible. MRI is a snapshot as well as a measurement, so it is repeated when the question changes rather than on a fixed calendar. And it does not replace the electrical assessment — scar raises the estimate of risk, but a decision about a defibrillator is made from a combination of features, of which the scan is only one.
The electrical assessment: not a formality
In cardiomyopathy, structure and rhythm risk are related but they are not the same thing. A heart with modest structural change can be the one whose rhythm fails, which is why every patient has an electrical assessment — and why it is repeated over the years rather than performed once and filed.
| Test | What it is looking for | What it changes |
|---|---|---|
| Twelve-lead ECG | The voltage and conduction patterns that suggest thickening, infiltration or scar — and, in some patients, pre-excitation suggesting an extra electrical pathway | Raises or lowers the suspicion of particular types, and provides the baseline against which every later ECG is read |
| Ambulatory (Holter) monitoring | How often and how fast the rhythm misbehaves over a day or more, including the runs that the patient never feels | Identifies the patients whose rhythm needs treating, as distinct from those whose symptoms have another explanation |
| Exercise testing | The blood-pressure response to exercise, the rhythm during effort, the gradient provoked by effort, and the patient's real exercise capacity | Provokes in obstructive disease what rest cannot, and an abnormal blood-pressure response to exercise is one of the features that raises the estimate of rhythm risk |
| Prolonged or implanted monitoring | The rhythm during a fainting spell that the tests above have not explained | Turns an unexplained fainting into a diagnosis, which changes whether the question of a defibrillator is opened at all |
One point about reading these tests. An ECG can be unusual in an athlete who has no disease at all, and unremarkable in a patient whose heart is genuinely thickened — the classic example being the patient whose ECG looks too normal for the thickness of the wall, which is itself a clue pointing towards infiltration. That is why the electrical assessment is read alongside the imaging rather than before it or after it, and why a normal ECG is never used on its own to close the question.
Blood markers and genetic testing
Two quite different kinds of blood test appear in a cardiomyopathy work-up, and they do different jobs: one measures the consequences, the other hunts the cause.
| Test | What it tells you | What it does not do |
|---|---|---|
| NT-proBNP or BNP | How much the muscle is being stretched and loaded — useful for following a trend and for separating a cardiac explanation from a lung one | It does not name the type or the cause, and a normal level does not exclude disease |
| Troponin | Whether heart muscle is being injured at the moment of the test, which separates an acute injury from a chronic picture | A mildly raised troponin has many causes other than a blocked artery, and a normal result says nothing about structure |
| Iron studies, kidney, liver and thyroid function, autoimmune screen | The acquired causes that can be treated: iron overload, kidney disease, an underactive thyroid, autoimmune or inflammatory disease | Mild abnormalities are common in people without cardiomyopathy at all, so they are read together with the imaging rather than in isolation |
| Protein electrophoresis and free light chains | Whether a plasma-cell disorder is producing the light chains responsible for AL amyloidosis — the form that must not be missed, because it needs urgent treatment of a different kind | A normal result does not exclude the transthyretin form of amyloidosis, which is investigated separately |
| Genetic testing, with counselling | Whether the disease is explained by an inherited variant, which then becomes the basis for testing relatives | It does not say when symptoms will start or how severe they will become, and a variant of uncertain significance is a real and frequent outcome rather than a failure of the test |
Genetic testing deserves its own paragraph, because the reason to do it is not always the patient in the room. Where a disease-causing variant is found, the family's screening changes character: instead of "everyone needs scans indefinitely", it becomes a targeted test for the relatives who carry the variant — and it identifies the relatives who do not, who can then be discharged from surveillance. That is why the test is offered even when the result will not alter the patient's own medication: the result is aimed at people who have not been examined yet.
Two conditions make genetic testing work as intended. The first is counselling before the test, so that the patient understands the difference between a result that explains the disease, a result that explains nothing, and a result that is still uncertain — and understands that a positive finding carries implications for relatives who have not been asked. The second is keeping the result where the family can use it, because the question will be asked again in twenty years, by a different generation. How relatives are screened, with what, and at what intervals is set out on the prevention page of this guide.
Scintigraphy, catheterisation and biopsy: tests used to settle a specific question
Three further tests are used selectively, and each exists to answer a question that the non-invasive work-up has left open. None of them is a routine part of diagnosis, and none should be performed to make a file look complete.
- Bone-tracer scintigraphy. In suspected transthyretin amyloidosis, a radiolabelled bone tracer that is taken up by the heart, taken together with blood tests that exclude a plasma-cell disorder, can establish the diagnosis without removing any muscle at all. Where the scan is positive and the bloods are consistent, the biopsy is avoided altogether — one of the few places in cardiology where imaging genuinely replaces tissue.
- Cardiac catheterisation. It measures the pressures inside the chambers directly, which is the surest way to demonstrate the high, stiff filling pattern of restrictive disease. In many patients it is also how coronary disease is excluded as the explanation for a weak, dilated heart — a step that is worth taking before the word cardiomyopathy is settled on, because a blockage that can be opened changes everything.
- Endomyocardial biopsy. A small sample of heart muscle, taken through a catheter from the inside of the right ventricle. Its clearest indications are the conditions in which the answer changes treatment immediately: suspected amyloidosis when the non-invasive tests disagree, sarcoidosis, giant-cell myocarditis and eosinophilic disease. Its limits are equally clear — the disease is often patchy, the sample is small, and the procedure carries a risk that has to be justified by what the result would alter.
The rule governing all three is the same: an invasive test earns its place when the result changes what happens next. A patient whose MRI has already identified the disease and whose rhythm risk has already been assessed does not need a biopsy to make the notes look thorough. Conversely, a patient whose treatment turns on distinguishing one infiltrative disease from another should not be left with an open question because the tests that could close it were judged too specialised to arrange.
What a complete assessment should answer
A cardiomyopathy record is complete when it can answer five questions. Anything less is a description rather than a diagnosis, and it leaves the decisions that follow without a foundation.
- Which type, and on what evidence — the imaging findings, the family history and, where relevant, the genetic result, stated as the basis for the label rather than assumed.
- What the heart is doing today — the pump function and the filling pattern, the exercise capacity, and the functional class measured against the patient's own baseline.
- What the rhythm risk is — the features that raise it, assembled explicitly, and a conclusion that is one of three: no device needed, the question should be revisited, or a defibrillator is indicated.
- What caused it — including whether a treatable acquired cause has been excluded, and an honest statement of what remains unknown. The search for the cause is the subject of the causes page.
- What happens next, and to whom — the monitoring plan for the patient and the screening plan for relatives, with names, tests and intervals rather than a general recommendation to "see a cardiologist".
It is worth asking for that summary in writing, and worth asking again a year later whether anything in it has changed. Cardiomyopathy is a disease in which the answers move: a wall thins after treatment, a rhythm appears that was not there before, a sibling's test result changes what the whole family knows. A record that is never revised is not a record of this disease.